CYP2C19基因多态性对质子泵抑制剂治疗胃食管反流病疗效影响的Meta分析

目的：系统评价药物代谢酶CYP2C19基因多态性与质子泵抑制剂治疗胃食管反流病疗效的关系，以期为临床治疗提供循证参考。方法检索PubMed、Embase、CBM、CNKI、WanFang data、CQVIP等数据库，收集CYP2C19基因多态性与质子泵抑制剂治疗胃食管反流病的临床文献。根据纳入和排除标准筛选文献、评价和提取数据后，采用RevMan 5.3软件进行Meta分析。结果共纳入4篇文献，包含347例对象。 Meta分析结果显示：CYP2C19强代谢型（EM）、中间代谢型（IM）与弱代谢型（PM）的胃食管反流病治愈率不存在统计学差异。结论 CYP2C19基因多态性不影响质子泵抑制剂对胃食管反流病的治愈率。

Meta-analysis of influence of CYP2C19 genetic polymorphisms on healing rates of gastroesophageal reflux disease using proton pump inhibitors

Objective To systematically review the influence of CYP2C19 genetic polymorphisms on healing rates of gastroesophageal reflux disease using proton pump inhibitors. Methods Such databases as PubMed, Embase, CBM, CNKI, WanFang data and CQVIP were electronically searched for clinical studies on the CYP2C19 genetic polymorphisms and proton pump inhibitors and gastroesophageal reflux disease. According to the inclusion and exclusion criteria,literatures were screened, and data were extracted, and the methodologically quality of included studies were also examined. Meta-analysis was then performed using RevMan 5.3 software. Results A total of 4 studies involving 347 subjects were included. The results of meta-analysis showed that CYP2C19 genetic polymorphism (extensive metabolizer, EM; intermediate metabolizer, IM; poor metabolizer, PM) of patients were not associated with healing rates of gastroesophageal reflux disease in the treatment of proton pump inhibitors. Conclusions CYP2C19 genetic polymorphism did not affect the healing rates of gastroesophageal reflux disease in the treatment of proton pump inhibitors.